جميع الدراسات
التوظيفالمرحلة 2تدخلي

WIRE - Novel Treatments in Renal Cell Cancer

This is a study for people with kidney cancer that can be removed with an operation. We are testing new medicines (called Olaparib, Cediranib, Volrustomig, or Rilvegostomig) given alone or in combination for a short time, usually a few weeks, right before surgery. The aim is to understand how these medicines affect the cancer and the body before the operation. We’re looking for early signs that the medicines are working by checking changes in the tumour or immune system. This could help us develop more effective treatments for kidney cancer in the future. The study involves up to 60 patients across different hospitals.

نظرة سريعة

الحالة
التوظيف
المرحلة
المرحلة 2
الراعي
CCTU- Cancer Theme
الهدف من التسجيل
134
ابدأ
27 يوليو 2020
التاريخ المتوقع للانتهاء
30 ديسمبر 2027

ما هو موضوع هذه الدراسة؟

This study, called WIRE, is exploring new ways to treat a type of kidney cancer known as renal cell cancer. This specific study focuses on patients whose cancer can be surgically removed. We're testing new drugs like Olaparib, Cediranib, Volrustomig, and Rilvegostomig. These medicines are given for a short period, typically a few weeks, right before you have your planned operation to remove the kidney tumour. This short treatment period is sometimes called a 'window of opportunity' because it allows us to see how the drugs affect the cancer before it's taken out.

The main goal is to understand how these new medicines work at a very early stage. We'll be looking for specific changes in the tumour, for example, by using special scans (MRI) or by checking certain cells in the body (like immune cells called CD8 T cells). By doing this, we hope to find early signs that a treatment is having an effect. This information is really important because it helps us learn which drugs might be most promising for future, larger studies and ultimately, for helping patients with kidney cancer.

This is a 'Phase 2' study, which means we're still in the early stages of testing these treatments. It's a non-randomised study, meaning you won't be randomly assigned to a treatment. Instead, the study design will guide which treatment group is best for each patient based on how previous patients responded. Up to 60 patients will take part across several hospitals. This research is vital to developing better, more targeted treatments for kidney cancer.

النقاط الرئيسية

  • Tests new medicines for kidney cancer that can be surgically removed.
  • Medicines are given for a short period before planned surgery.
  • Aims to understand how new treatments affect the cancer and immune system.
  • You will receive close monitoring and care during the study.
  • Your participation helps advance future kidney cancer treatments.
  • يمكنك الانسحاب من الدراسة في أي وقت دون التأثير على رعايتك.

من قد يكون مؤهلاً؟

To join this study, you need to be at least 18 years old and generally well enough to take part. This includes being able to move around without too much difficulty and having a good quality of life. Importantly, you must have kidney cancer that doctors believe can be fully removed by surgery. We'll need to confirm your specific type of kidney cancer through a biopsy.

There are also some important things that would mean you couldn't join. For example, if you've already had certain types of treatment for your kidney cancer, such as specific targeted drugs or immunotherapy, you wouldn't be able to participate. This is because we need to see how these new medicines work on their own or in new combinations, without the effects of previous treatments.

Your doctors will check your general health, including how your organs are working, to make sure it's safe for you to take the study medicines. You also need to have at least one measurable tumour that can be tracked with scans during the study.

هل يمكن أن تناسبك هذه الدراسة؟

أجب عن هذه الأسئلة السريعة لترى ما إذا كنت مؤهلاً. هذا دليل فقط - الفريق البحثي هو الذي يتخذ القرار النهائي.

  1. هل عمرك 18 سنة أو أكثر؟
  2. Do you have kidney cancer that your doctor says can be removed by surgery?
  3. Have you *not* had previous treatment with certain targeted drugs or immunotherapy for your kidney cancer?
  4. Are you generally well enough to take part in a study?
  5. Do you have at least one tumour that can be measured on scans?
أجب عن كل سؤال لترى نتيجتك.

ماذا يتضمن المشاركة؟

If you decide to join, you'll first have a screening period, which lasts about 4 weeks. During this time, you'll have tests and scans to make sure you're suitable for the study. If you qualify, you'll then start taking one or more study medicines, usually as tablets, for at least 2 weeks before your planned surgery to remove the kidney tumour. You'll continue taking the medicine right up until shortly before your operation.

During this time, you might have extra clinic visits or phone calls, especially if you're still on the medicine for a longer period. After your surgery, which will be carried out as standard care, you'll have follow-up appointments at 6 weeks and 3 months to check on your recovery and health. We'll also do special scans (MRI) or blood tests to see how the treatment affected your tumour or immune system. The overall time you're involved with the study, including follow-up, will vary but will be relatively short compared to longer-term cancer treatments.

المخاطر والفوائد المحتملة

Taking part in this study may offer some potential benefits. You will receive close medical attention and access to new treatments that are not yet widely available. The information gained from your participation will help doctors better understand how to treat kidney cancer in the future, potentially leading to more effective options for others. However, there's no guarantee that the treatment will directly benefit you, as this is an early-stage study designed to understand how the drugs work. As with all medicines, there are potential risks, and you might experience side effects from the study drugs. These side effects can vary, and the study team will monitor you closely for any issues and explain them to you before you agree to take part. There may also be inconvenience from extra hospital visits and tests. It's important to remember that joining this study is entirely your choice. You can decide to leave the study at any time, for any reason, without it affecting your usual medical care.

المواقع (7)

  • مستشفى أدينبروك
    الرمز البريدي المؤكد
    كامبريدج، المملكة المتحدة· التوظيف
  • Western General Hospital, Edinburgh, EH4 2XU
    الرمز البريدي المؤكد
    إدنبرة، المملكة المتحدة· التوظيف
  • Royal Devon University Healthcare NHSFT, Exeter, EX2 5DW
    الرمز البريدي المؤكد
    إكستر، المملكة المتحدة· التوظيف
  • Beatson Institute for Cancer Research
    الرمز البريدي المؤكد
    غلاسكو، المملكة المتحدة· التوظيف
  • مؤسسة الرعاية الصحية لكلية إمبريال التابعة لهيئة الخدمات الصحية الوطنية
    الرمز البريدي المؤكد
    لندن، المملكة المتحدة· التوظيف
  • Churchill Hospital, Old Road, Headington, Oxford, OX3 7LE
    الرمز البريدي المؤكد
    أوكسفورد، المملكة المتحدة· التوظيف
  • Weston Park Hospital
    الرمز البريدي المؤكد
    شيفيلد، المملكة المتحدة· لم يبدأ التوظيف بعد

أسئلة شائعة

ما نوع السرطان الذي تدرس هذه الدراسة؟

This study is specifically for a type of kidney cancer called renal cell cancer that doctors believe can be completely removed by surgery.

What are the new medicines being tested?

We are testing several new medicines, either alone or in combination. These include Olaparib, Cediranib, Volrustomig, and Rilvegostomig.

How long will I take the study medicine?

You will take the medicine for a short time, usually at least 2 weeks, right before your planned kidney surgery.

Will I still have my surgery if I join this study?

Yes, your surgery to remove the kidney tumour will still happen as planned and is part of your standard care.

ما هو الهدف الرئيسي من هذه الدراسة؟

The main purpose is to see how these new medicines affect the cancer and the body before surgery, to help us find better treatments for kidney cancer in the future.

كيفية معرفة المزيد

CCTU Cancer Theme

تحدث دائمًا إلى طبيبك العام أو الأخصائي قبل اتخاذ قرار بالمشاركة في دراسة.

هل أنت مهتم بالمشاركة؟

سجل اهتمامك

شارك تفاصيلك وفريق البحث لـ "WIRE - Novel Treatments in Renal Cell Cancer… "سيتواصل معك إذا كنت مؤهلاً. تحدث دائمًا إلى طبيبك قبل الموافقة على المشاركة.

نقاش

مناقشة المجتمع

مدعوم من منتدانا في community.patient.info. يرجى التحلي بالاحترام — هذه ليست نصيحة طبية.